Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab plus steroid pulses versus steroid pulses alone for acute cellular kidney allograft rejection with CD20-positive infiltrates
2007-005503-17Phase 3Terminated
- Sponsor
- Medizinische Hochschule Hannover
- Start
- Oct 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of rituximab, corticosteroids in kidney allograft rejection, Acute cellular kidney allograft rejection, sponsored by Medizinische Hochschule Hannover. Started Oct 2007; status: terminated.
02
Drugs
rituximabcorticosteroids
03
Conditions
kidney allograft rejectionAcute cellular kidney allograft rejection
Beyond the preview
Go deeper on 2007-005503-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005503-17.